Regeneron Pharmaceuticals reported first-quarter 2024 financial results Thursday that missed consensus Wall Street expectations for earnings and revenue.
Analysts expected Regeneron to earn $10.18 per share and report $3.23 billion in sales in the quarter. However, the company’s Q1 adjusted earnings came in at $9.55 per share with $3.15 billion in sales.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,